Arcutis Biotherapeutics, Inc. (ARQT) vs Dyne Therapeutics, Inc. (DYN)
A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Dyne Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARQT
Arcutis Biotherapeutics, Inc.
$25.15HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
DYN
Dyne Therapeutics, Inc.
$15.44HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ARQT vs DYN
growth of $100 · dividends reinvested · last 6yARQT -2.1% (-0.4%/yr)DYN -35.4% (-7.0%/yr)ARQT compounded faster over this window
ARQT DYN
ARQT vs DYN: by the numbers
- •ARQT is the larger company ($3.15B vs $2.88B market cap).
- •ARQT is profitable (6.15% net margin) while DYN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ARQT | DYN |
|---|---|---|
| P/E ratio | 120.62 | N/A |
| Forward P/E | 50.59 | N/A |
| P/S ratio | 6.78 | N/A |
| P/B ratio | 14.26 | 4.11 |
| EV / EBITDA | 86.71 | N/A |
| FCF yield | 1.24% | N/A |
Profitability
| Metric | ARQT | DYN |
|---|---|---|
| Gross margin | 91.14% | 0.00% |
| Operating margin | -3.25% | 0.00% |
| Net margin | 6.15% | 0.00% |
| ROE | 12.93% | -73.97% |
| ROIC | 9.95% | -58.28% |
Growth (annualized)
| Metric | ARQT | DYN |
|---|---|---|
| Total return CAGR (5Y) | -0.28% | -0.38% |
Frequently asked
- Is ARQT or DYN more profitable?
- ARQT runs the higher net margin — ARQT at 6.15% versus DYN at 0.00%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.